Welcome, please login

New Approach riVaroxaban Inhibition of Factor Xa in a Global trial vs ASA to prevenT Embolism in Embolic Stroke of Undetermined Source

© 2025 Population Health Research Institute
Unauthorized use of this system is strictly prohibited. Your IP 192.168.175.44

Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ESUS), comparing rivaroxaban 15 mg once daily with aspirin 100 mg (NAVIGATE ESUS)